Department of Haematology, Derriford Hospital, Plymouth PL6 8DH, UK.
Int J Hematol. 2010 Mar;91(2):322-5. doi: 10.1007/s12185-009-0489-9.
Autoimmune haemolytic anaemia (AIHA) is a well-recognised complication of lymphoproliferative disorders, and has been reported in association with all B and T cell non-Hodgkin lymphoma subtypes with the exception of mantle cell lymphoma (MCL). We describe herein a case of MCL diagnosed in an initially asymptomatic 66-year-old woman who developed transfusion-dependent AIHA 6 months later coincident with lymphoma progression. The AIHA failed to respond satisfactorily to conventional treatment (high-dose oral prednisolone) but rapidly resolved following commencement of non-rituximab-containing combination chemotherapy in parallel with complete remission of the lymphoma. This is the first of such cases to be described in the literature and confirms that the immune environment of MCL can predispose to AIHA in the same way as in other lymphoma subtypes. Despite this being an infrequent occurrence, clinicians should be aware that AIHA is a potential complication of MCL and may be more successfully controlled by treating the underlying lymphoma rather than relying on conventional anti-haemolytic strategies such as steroids.
自身免疫性溶血性贫血(AIHA)是一种公认的淋巴增殖性疾病的并发症,已在除套细胞淋巴瘤(MCL)以外的所有 B 和 T 细胞非霍奇金淋巴瘤亚型中报道。我们在此描述了一例最初无症状的 66 岁女性 MCL 病例,她在 6 个月后出现依赖输血的 AIHA,同时伴有淋巴瘤进展。AIHA 对常规治疗(大剂量口服泼尼松龙)反应不佳,但在开始与淋巴瘤完全缓解同时进行不含利妥昔单抗的联合化疗后迅速缓解。这是文献中首例此类病例,证实了 MCL 的免疫环境与其他淋巴瘤亚型一样容易导致 AIHA。尽管这种情况很少见,但临床医生应该意识到 AIHA 是 MCL 的潜在并发症,通过治疗潜在的淋巴瘤而不是依赖于类固醇等常规抗溶血策略,可能会更成功地控制 AIHA。